Mizuho Securities analyst Mario Corso defended Avanir Pharmaceuticals (NASDAQ: AVNR) in response to a negative report by Gravity Research yesterday. In Corso's view, concerns raised by Gravity are "off the mark."
The report raised concerns about off label marketing and patents.
In Corso's view focus on Nuedexta IP and marketing are overblown. He continues to see Avanir having robust patents and high change of winning generic lawsuit.
Mizuho Securities has a Buy rating on Avanir Pharmaceuticals with a price target of $11.00
Since you allegedly have so much faith in Mizuho you presumably believ their breakeven date of 2016 or 2017 could be accurate. Yet you selectively don't even mention that while you plaster Mizuho's size and price target all over this message board regularly along with all the other analyst predictions. At least the predictions that you find acceptably "rosy".